ARTBIO is a clinical-stage radiopharmaceutical company developing Pb-212–based alpha radioligand therapies through proprietary AlphaDirect™ generators enabling distributed production and supply-chain networks, with lead candidate AB001 in first-in-human trials.
artbio.comPart of: Boston tech scene from Fundable